These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24684229)

  • 1. Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Sorà F; Autore F; Chiusolo P; Marietti S; Bayer J; Laurenti L; Giammarco S; Ausoni G; Leone G; Sica S
    Leuk Lymphoma; 2014 Dec; 55(12):2958-60. PubMed ID: 24684229
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia.
    Boklan JL; Walsh AM; de la Maza MC; Su LL; Nizzi FA; Schafernak KT
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):456-457. PubMed ID: 29668550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
    Keskin D; Sadri S; Eskazan AE
    Drug Des Devel Ther; 2016; 10():3355-3361. PubMed ID: 27784993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
    [No Abstract]   [Full Text] [Related]  

  • 6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis.
    Huho AN; Issaq N; Iacobas I; Elghetany TM; López-Terrada D; Fisher KE; Punia JN
    Pediatr Dev Pathol; 2018; 21(1):100-104. PubMed ID: 29187020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
    Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM; Melo JV
    N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
    Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
    Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia.
    Galimberti S; Fontanelli G; Barsotti S; Ricci F; Guerrini F; Baratè C
    Blood Cells Mol Dis; 2015 Oct; 55(3):211-2. PubMed ID: 26227847
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic myeloid leukemia: reversing the chronic phase.
    Goldman JM
    J Clin Oncol; 2010 Jan; 28(3):363-5. PubMed ID: 20008612
    [No Abstract]   [Full Text] [Related]  

  • 14. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors in chronic myeloid leukemia.
    Sawyers CL; Druker B
    Cancer J Sci Am; 1999; 5(2):63-9. PubMed ID: 10198725
    [No Abstract]   [Full Text] [Related]  

  • 16. Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead.
    Amitai I; Leader A; Raanani P
    Acta Haematol; 2016; 136(1):43-4. PubMed ID: 27160309
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 18. Coronary thrombosis in a patient with leukemic thrombocytosis: which was the best treatment?
    Delcrè S; Bollati M; Moretti C; Biondi-Zoccai GG; Anselmino M; Laudito A; Sheiban I
    Minerva Cardioangiol; 2008 Apr; 56(2):263. PubMed ID: 18319708
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
    Guilhot F
    Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
    [No Abstract]   [Full Text] [Related]  

  • 20. The second generation of BCR-ABL tyrosine kinase inhibitors.
    Tauchi T; Ohyashiki K
    Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.